Skip to main content
. 2019 Jun 18;11:5513–5522. doi: 10.2147/CMAR.S183519

Table 3.

Comparison of perioperative factors in different surgical methods

Mastectomy BCS X2 P-value
No. of patients 49 31
Anesthetic method 0.016 0.899
 SEV 23 (46.9) 15 (48.4)
 TIVA 26 (53.1) 16 (51.6)
Intraoperation opioids
 Remifentanil 26 (53.1) 16 (51.6) 0.016 0.899
 Fentanyl 36 (73.5) 24 (77.4) 0.158 0.691
Postoperative analgesia
 Fentanyl 2 (4.1) 4 (12.9) 1.048 0.306
 Flurbiprofen axetil (50mg) 49 (100) 31 (100)
 Flurbiprofen axetil (100mg) 7 (14.3) 8 (25.8) 1.654 0.198
Serological indices
 Preoperative MDSCs (%) 1.02 (0.67–2.17) 1.25 (1.02–2.03) 0.230*
  PMN-MDSCs 0.74 (−0.37–1.04) 0.75 (0.57–1.20) 0.390
  Mo-MDSCs 0.44 (0.19–1.18) 0.53 (0.34–0.96) 0.544
 Postoperative MDSC (%) 1.67 (1.15–3.92) 2.93 (1.65–5.00) 0.040*
  PMN-MDSCs 1.04 (0.68–1.61) 1.18 (0.81–1.90) 0.356
  Mo-MDSCs 0.88 (0.41–1.98) 1.41 (0.64–3.06) 0.351
Postoperative VAS
 VAS for 2 hrs 2.0 (1.0–2.0) 1.0 (0.0–2.0) 0.108*
 VAS for 24 hrs 1.0 (1.0–2.0) 2.0 (1.0–3.0) 0.044*

Notes: All data are presented as No. (%) or median (25–75% interquartile range), n=120. *Mann–Whitney test. Chi-square (X2) test.

Abbreviations: BCS, breast-conserving surgery; SEV, sevoflurane-based anesthetic; TIVA, total intravenous anesthetic; Mo-MDSCs, monocytic myeloid-derived suppressor cells; PMN-MDSCs, polymorphonuclear myeloid-derived suppressor cells.